Galapagos: major deal with Gilead

(CercleFinance.com) - Galapagos jumped 18% in Amsterdam after closing a 10-year global research and development collaboration with Gilead Sciences, through which the latter will gain access to the pharmaceutical lab's innovative portfolio.


In return, Galapagos will receive an initial payment of 3.95 billion dollars and a 1.1 billion equity investment from Gilead, which it will use to expand and accelerate its R&D programmes.

The portfolio in question includes six molecules currently in clinical trials, more than 20 preclinical programmes and a proven drug discovery platform, with Gilead receiving the rights to commercialise these in all countries outside Europe.

Copyright (c) 2019 CercleFinance.com. All rights reserved.